Related Experiment Video
Updated: May 10, 2026
Validated Immunochemical Assay for Comprehensive Determination of the Human Epidermal Growth Factor Receptor 2 Released from and Bound to Cells
Published on: May 9, 2025
A gene expression profile indicative of early stage HER2 targeted therapy response
Fiona O'Neill1, Stephen F Madden, Martin Clynes
1Molecular Therapeutics for Cancer Ireland, National Institute for Cellular Biotechnology, Dublin City University, Glasnevin, Dublin 9, Ireland. fiona.oneill4@mail.dcu.ie
Background:
Efficacious application of HER2-targetting agents requires the identification of novel predictive biomarkers. Lapatinib, afatinib and neratinib are tyrosine kinase inhibitors (TKIs) of HER2 and EGFR growth factor receptors. A panel of breast cancer cell lines was treated with these agents, trastuzumab, gefitinib and cytotoxic therapies and the expression pattern of a specific panel of genes using RT-PCR was investigated as a potential marker of early drug response to HER2-targeting therapies.
Results:
Treatment of HER2 TKI-sensitive SKBR3 and BT474 cell lines with lapatinib, afatinib and neratinib induced an increase in the expression of RB1CC1, ERBB3, FOXO3a and NR3C1. The response directly correlated with the degree of sensitivity. This expression pattern switched from up-regulated to down-regulated in the HER2 expressing, HER2-TKI insensitive cell line MDAMB453. Expression of the CCND1 gene demonstrated an inversely proportional response to drug exposure. A similar expression pattern was observed following the treatment with both neratinib and afatinib. These patterns were retained following exposure to traztuzumab and lapatinib plus capecitabine. In contrast, gefitinib, dasatinib and epirubicin treatment resulted in a completely different expression pattern change.
Conclusions:
In these HER2-expressing cell line models, lapatinib, neratinib, afatinib and trastuzumab treatment generated a characteristic and specific gene expression response, proportionate to the sensitivity of the cell lines to the HER2 inhibitor.Characterisation of the induced changes in expression levels of these genes may therefore give a valuable, very early predictor of the likely extent and specificity of tumour HER2 inhibitor response in patients, potentially guiding more specific use of these agents.
Insights
Researchers identified specific gene expression patterns in breast cancer cell lines treated with HER2-targeting therapies. These patterns, including RB1CC1 and ERBB3, predict early drug response to HER2 inhibitors like lapatinib.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacogenomics
Background:
- Accurate prediction of response to HER2-targeting therapies is crucial for effective breast cancer treatment.
- Tyrosine kinase inhibitors (TKIs) such as lapatinib, afatinib, and neratinib target HER2 and EGFR pathways.
- Novel predictive biomarkers are needed to guide the clinical application of HER2-targeted agents.
Purpose of the Study:
- To investigate gene expression patterns as early indicators of drug response to HER2-targeting therapies.
- To identify specific gene expression profiles associated with sensitivity and resistance to HER2 TKIs.
- To evaluate the potential of gene expression analysis for guiding the use of HER2 inhibitors.
Main Methods:
- Treatment of HER2-expressing breast cancer cell lines (SKBR3, BT474, MDAMB453) with various HER2-targeting agents (lapatinib, afatinib, neratinib, trastuzumab) and control drugs.
- Quantitative analysis of gene expression patterns using RT-PCR.
- Correlation of gene expression changes with cellular sensitivity to HER2 inhibitors.
Main Results:
- HER2 TKI-sensitive cell lines showed increased expression of RB1CC1, ERBB3, FOXO3a, and NR3C1 upon treatment with lapatinib, afatinib, and neratinib.
- A switch from up-regulation to down-regulation of these genes was observed in HER2-TKI insensitive cell lines.
- CCND1 gene expression was inversely proportional to drug exposure, with similar patterns for neratinib and afatinib.
Conclusions:
- Lapatinib, neratinib, afatinib, and trastuzumab induced specific gene expression responses in HER2-expressing cell lines, correlating with drug sensitivity.
- Characterizing these gene expression changes may serve as an early predictor of tumor response to HER2 inhibitors.
- This approach could potentially guide the more precise application of HER2-targeted therapies in patients.
